CoChat

A liver Hif-2α–Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition

Open access
Wei, Kevin, Piecewicz, Stephanie M, McGinnis, Lisa M, Taniguchi, Cullen M, Wiegand, Stanley J, Anderson, Keith, Chan, Carol W-M, Mulligan, Kimberly X, Kuo, David, Yuan, Jenny, Vallon, Mario, Morton, Lori C, Lefai, Etienne, Simon, M Celeste, Maher, Jacquelyn J, Mithieux, Gilles, Rajas, Fabienne, Annes, Justin P, McGuinness, Owen P, Thurston, Gavin, Giaccia, Amato J, Kuo, Calvin J · 2013 · Nature Medicine
Cited by 101

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Insulin initiates diverse hepatic metabolic responses, including gluconeogenic suppression and induction of glycogen synthesis and lipogenesis. The liver possesses a rich sinusoidal capillary network with a higher degree of hypoxia and lower gluconeogenesis in the perivenous zone as compared to the rest of the organ. Here, we show that diverse vascular endothelial growth factor (VEGF) inhibitors improved glucose tolerance in nondiabetic C57BL/6 and diabetic db/db mice, potentiating hepatic insulin signaling with lower gluconeogenic gene expression, higher glycogen storage and suppressed hepatic glucose production. VEGF inhibition induced hepatic hypoxia through sinusoidal vascular regression and sensitized liver insulin signaling through hypoxia-inducible factor-2α (Hif-2α, encoded by Epas1) stabilization. Notably, liver-specific constitutive activation of HIF-2α, but not HIF-1α, was sufficient to augment hepatic insulin signaling through direct and indirect induction of insulin receptor substrate-2 (Irs2), an essential insulin receptor adaptor protein. Further, liver Irs2 was both necessary and sufficient to mediate Hif-2α and Vegf inhibition effects on glucose tolerance and hepatic insulin signaling. These results demonstrate an unsuspected intersection between Hif-2α−mediated hypoxic signaling and hepatic insulin action through Irs2 induction, which can be co-opted by Vegf inhibitors to modulate glucose metabolism. These studies also indicate distinct roles in hepatic metabolism for Hif-1α, which promotes glycolysis, and Hif-2α, which suppresses gluconeogenesis, and suggest new treatment approaches for type 2 diabetes mellitus.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nm.3295

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 33

  1. Leavens, K.F. & Birnbaum, M.J. Insulin signaling to hepatic lipid metabolism in health and disease. Crit. Rev. Biochem. Mol. Biol. 46, 200–215 (2011). · DOI · Paper page
  2. Jungermann, K. Zonation of metabolism and gene expression in liver. Histochem. Cell Biol. 103, 81–91 (1995). · DOI
  3. Dong, X. et al. Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth. J. Clin. Invest. 116, 101–114 (2006). · DOI · Paper page
  4. Zhong, L. et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1α. Cell 140, 280–293 (2010). · DOI · Paper page
  5. Hu, C.J. et al. Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 α (HIF-1α) and HIF-2α in stem cells. Mol. Cell Biol. 26, 3514–3526 (2006). · DOI · Paper page
  6. Ferrara, N., Gerber, H.P. & LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 9, 669–676 (2003). · DOI · Paper page
  7. Alitalo, K. & Carmeliet, P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1, 219–227 (2002). · DOI · Paper page
  8. Kamba, T. et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am. J. Physiol. Heart Circ. Physiol. 290, H560–H576 (2006). · DOI · Paper page
  9. Billemont, B. et al. Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br. J. Cancer 99, 1380–1382 (2008). · DOI · Paper page
  10. Hagberg, C.E. et al. Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature 490, 426–430 (2012). · DOI · Paper page
  11. Kuo, C.J. et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc. Natl. Acad. Sci. USA 98, 4605–4610 (2001). · DOI · Paper page
  12. Tam, B.Y. et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat. Med. 12, 793–800 (2006). · DOI · Paper page
  13. Papadopoulos, N. et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15, 171–185 (2012). · DOI · Paper page
  14. Liang, W.C. et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J. Biol. Chem. 281, 951–961 (2006). · DOI · Paper page
  15. Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59, 5209–5218 (1999).
  16. Fan, X. et al. VEGF blockade inhibits angiogenesis and reepithelialization of endometrium. FASEB J. 22, 3571–3580 (2008). · DOI · Paper page
  17. Mancuso, M.R. et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 116, 2610–2621 (2006). · DOI · Paper page
  18. Canettieri, G. et al. Dual role of the coactivator TORC2 in modulating hepatic glucose output and insulin signaling. Cell Metab. 2, 331–338 (2005). · DOI
  19. Ide, T. et al. SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat. Cell Biol. 6, 351–357 (2004). · DOI · Paper page
  20. Shimomura, I. et al. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol. Cell 6, 77–86 (2000). · doi:10.1016/s1097-2765(05)00010-9 · Paper page
  21. Lecomte, V. et al. A new role for sterol regulatory element binding protein 1 transcription factors in the regulation of muscle mass and muscle cell differentiation. Mol. Cell Biol. 30, 1182–1198 (2010). · DOI · Paper page
  22. Yeo, E.J., Cho, Y.S., Kim, M.S. & Park, J.W. Contribution of HIF-1α or HIF-2α to erythropoietin expression: in vivo evidence based on chromatin immunoprecipitation. Ann. Hematol. 87, 11–17 (2008). · DOI
  23. Covello, K.L. et al. HIF-2α regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 20, 557–570 (2006). · DOI · Paper page
  24. Rankin, E.B. et al. Hypoxia-inducible factor 2 regulates hepatic lipid metabolism. Mol. Cell Biol. 29, 4527–4538 (2009). · DOI · Paper page
  25. Wang, X.L. et al. Ablation of ARNT/HIF1β in liver alters gluconeogenesis, lipogenic gene expression, and serum ketones. Cell Metab. 9, 428–439 (2009). · DOI · Paper page
  26. Scully, M.S. et al. A novel EPO receptor agonist improves glucose tolerance via glucose uptake in skeletal muscle in a mouse model of diabetes. Exp. Diabetes Res. 2011, 910159 (2011). · DOI
  27. Meng, R., Zhu, D., Bi, Y., Yang, D. & Wang, Y. Erythropoietin inhibits gluconeogenesis and inflammation in the liver and improves glucose intolerance in high-fat diet-fed mice. PLoS ONE 8, e53557 (2013). · DOI
  28. Mardilovich, K. & Shaw, L.M. Hypoxia regulates insulin receptor substrate-2 expression to promote breast carcinoma cell survival and invasion. Cancer Res. 69, 8894–8901 (2009). · DOI
  29. Taniguchi, C.M. et al. Cross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes. Nat. Med. doi:10.1038/nm.3294. · DOI · Paper page
  30. Qu, A. et al. Hypoxia-inducible transcription factor 2α promotes steatohepatitis through augmenting lipid accumulation, inflammation, and fibrosis. Hepatology 54, 472–483 (2011). · DOI · Paper page
  31. Jacobi, J. et al. Discordant effects of a soluble VEGF receptor on wound healing and angiogenesis. Gene Ther. 11, 302–309 (2004). · DOI
  32. Ayala, J.E. et al. Hyperinsulinemic-euglycemic clamps in conscious, unrestrained mice. J. Vis. Exp. 57, 3188 (2011).
  33. Mulligan, K.X., Morris, R.T., Otero, Y.F., Wasserman, D.H. & McGuinness, O.P. Disassociation of muscle insulin signaling and insulin-stimulated glucose uptake during endotoxemia. PLoS ONE 7, e30160 (2012). · DOI

Cited by

Metadata

Authors
Wei, K., Piecewicz, S. M., McGinnis, L. M., Taniguchi, C. M., Wiegand, S. J., Anderson, K., Chan, C. W.-M., Mulligan, K. X., Kuo, D., Yuan, J., Vallon, M., Morton, L. C., Lefai, E., Simon, M. C., Maher, J. J., Mithieux, G., Rajas, F., Annes, J. P., McGuinness, O. P., Thurston, G., Giaccia, A. J., & Kuo, C. J.
Venue
Nature Medicine
Published
2013-09-15
Volume
19
Issue
10
Pages
1331-1337
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2077103634
Cited by
101
References
12
FWCI
4.44
Type
journal article
Language
en
Open access
green
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.